Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | International Braz J Urol (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000400724 |
Resumo: | ABSTRACT Objectives To evaluate the diagnostic performance and interobserver agreement of PI-RADS v2. Materials and Methods In this Institutional Review Board approved single-center retrospective study, 98 patients with clinically suspected PCa who underwent 3-T multiparametric MRI followed by MRI/TRUS fusion-guided prostate biopsy were included from June 2013 to February 2015. Two radiologists (R1 and R2) with 8 and 1 years of experience in abdominal radiology reviewed the MRI scans and assigned PI-RADS v2 scores in all prostate zones. PI-RADS v2 were compared to MRI/TRUS fusion-guided biopsy results, which were classified as negative, PCa, and significant PCa (sPCa). Results Sensitivity, specificity, NPV, PPV and accuracy for PCa was 85.7% (same for all metrics) for R1 and 81.6%, 79.6%, 81.2%, 80.0% and 80.6% for R2. For detecting sPCa, the corresponding values were 95.3%, 85.4%, 95.9%, 83.7% and 89.8% for R1 and 93.0%, 81.8%, 93.7%, 86.7% and 86.7% for R2. There was substantial interobserver agreement in assigning PI-RADS v2 score as negative (1, 2, 3) or positive (4, 5) (Kappa=0.78). On multivariate analysis, PI-RADS v2 (p <0.001) was the only independent predictor of sPCa compared with age, abnormal DRE, prostate volume, PSA and PSA density. Conclusions Our study population demonstrated that PI-RADS v2 had high diagnostic accuracy, substantial interobserver agreement, and it was the only independent predictor of sPCa. |
id |
SBU-1_f6ac6be90a82a6ae95b676f987b1cc91 |
---|---|
oai_identifier_str |
oai:scielo:S1677-55382019000400724 |
network_acronym_str |
SBU-1 |
network_name_str |
International Braz J Urol (Online) |
repository_id_str |
|
spelling |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?ProstateMagnetic Resonance ImagingNeoplasmsProstatic NeoplasmsABSTRACT Objectives To evaluate the diagnostic performance and interobserver agreement of PI-RADS v2. Materials and Methods In this Institutional Review Board approved single-center retrospective study, 98 patients with clinically suspected PCa who underwent 3-T multiparametric MRI followed by MRI/TRUS fusion-guided prostate biopsy were included from June 2013 to February 2015. Two radiologists (R1 and R2) with 8 and 1 years of experience in abdominal radiology reviewed the MRI scans and assigned PI-RADS v2 scores in all prostate zones. PI-RADS v2 were compared to MRI/TRUS fusion-guided biopsy results, which were classified as negative, PCa, and significant PCa (sPCa). Results Sensitivity, specificity, NPV, PPV and accuracy for PCa was 85.7% (same for all metrics) for R1 and 81.6%, 79.6%, 81.2%, 80.0% and 80.6% for R2. For detecting sPCa, the corresponding values were 95.3%, 85.4%, 95.9%, 83.7% and 89.8% for R1 and 93.0%, 81.8%, 93.7%, 86.7% and 86.7% for R2. There was substantial interobserver agreement in assigning PI-RADS v2 score as negative (1, 2, 3) or positive (4, 5) (Kappa=0.78). On multivariate analysis, PI-RADS v2 (p <0.001) was the only independent predictor of sPCa compared with age, abnormal DRE, prostate volume, PSA and PSA density. Conclusions Our study population demonstrated that PI-RADS v2 had high diagnostic accuracy, substantial interobserver agreement, and it was the only independent predictor of sPCa.Sociedade Brasileira de Urologia2019-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000400724International braz j urol v.45 n.4 2019reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2018.0382info:eu-repo/semantics/openAccessViana,Publio Cesar CavalcantiHorvat,NatallySantos Júnior,Valter Ribeiro dosLima,Thais CarneiroRomão,Davi dos SantosCerri,Luciana Mendes de OliveiraCastro,Marilia Germanos deVargas,Herbert AlbertoMiranda,Júlia AzevedoLeite,Claudia da CostaCerri,Giovanni Guidoeng2019-08-30T00:00:00Zoai:scielo:S1677-55382019000400724Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2019-08-30T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false |
dc.title.none.fl_str_mv |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI? |
title |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI? |
spellingShingle |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI? Viana,Publio Cesar Cavalcanti Prostate Magnetic Resonance Imaging Neoplasms Prostatic Neoplasms |
title_short |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI? |
title_full |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI? |
title_fullStr |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI? |
title_full_unstemmed |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI? |
title_sort |
Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI? |
author |
Viana,Publio Cesar Cavalcanti |
author_facet |
Viana,Publio Cesar Cavalcanti Horvat,Natally Santos Júnior,Valter Ribeiro dos Lima,Thais Carneiro Romão,Davi dos Santos Cerri,Luciana Mendes de Oliveira Castro,Marilia Germanos de Vargas,Herbert Alberto Miranda,Júlia Azevedo Leite,Claudia da Costa Cerri,Giovanni Guido |
author_role |
author |
author2 |
Horvat,Natally Santos Júnior,Valter Ribeiro dos Lima,Thais Carneiro Romão,Davi dos Santos Cerri,Luciana Mendes de Oliveira Castro,Marilia Germanos de Vargas,Herbert Alberto Miranda,Júlia Azevedo Leite,Claudia da Costa Cerri,Giovanni Guido |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Viana,Publio Cesar Cavalcanti Horvat,Natally Santos Júnior,Valter Ribeiro dos Lima,Thais Carneiro Romão,Davi dos Santos Cerri,Luciana Mendes de Oliveira Castro,Marilia Germanos de Vargas,Herbert Alberto Miranda,Júlia Azevedo Leite,Claudia da Costa Cerri,Giovanni Guido |
dc.subject.por.fl_str_mv |
Prostate Magnetic Resonance Imaging Neoplasms Prostatic Neoplasms |
topic |
Prostate Magnetic Resonance Imaging Neoplasms Prostatic Neoplasms |
description |
ABSTRACT Objectives To evaluate the diagnostic performance and interobserver agreement of PI-RADS v2. Materials and Methods In this Institutional Review Board approved single-center retrospective study, 98 patients with clinically suspected PCa who underwent 3-T multiparametric MRI followed by MRI/TRUS fusion-guided prostate biopsy were included from June 2013 to February 2015. Two radiologists (R1 and R2) with 8 and 1 years of experience in abdominal radiology reviewed the MRI scans and assigned PI-RADS v2 scores in all prostate zones. PI-RADS v2 were compared to MRI/TRUS fusion-guided biopsy results, which were classified as negative, PCa, and significant PCa (sPCa). Results Sensitivity, specificity, NPV, PPV and accuracy for PCa was 85.7% (same for all metrics) for R1 and 81.6%, 79.6%, 81.2%, 80.0% and 80.6% for R2. For detecting sPCa, the corresponding values were 95.3%, 85.4%, 95.9%, 83.7% and 89.8% for R1 and 93.0%, 81.8%, 93.7%, 86.7% and 86.7% for R2. There was substantial interobserver agreement in assigning PI-RADS v2 score as negative (1, 2, 3) or positive (4, 5) (Kappa=0.78). On multivariate analysis, PI-RADS v2 (p <0.001) was the only independent predictor of sPCa compared with age, abnormal DRE, prostate volume, PSA and PSA density. Conclusions Our study population demonstrated that PI-RADS v2 had high diagnostic accuracy, substantial interobserver agreement, and it was the only independent predictor of sPCa. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-08-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000400724 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000400724 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/s1677-5538.ibju.2018.0382 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Urologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Urologia |
dc.source.none.fl_str_mv |
International braz j urol v.45 n.4 2019 reponame:International Braz J Urol (Online) instname:Sociedade Brasileira de Urologia (SBU) instacron:SBU |
instname_str |
Sociedade Brasileira de Urologia (SBU) |
instacron_str |
SBU |
institution |
SBU |
reponame_str |
International Braz J Urol (Online) |
collection |
International Braz J Urol (Online) |
repository.name.fl_str_mv |
International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU) |
repository.mail.fl_str_mv |
||brazjurol@brazjurol.com.br |
_version_ |
1750318076865282048 |